Investigational drug · Phase 2
MBS303
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Non-Hodgkin's Lymphoma.
Phase 2Last checked: Nov 19, 2026Latest source record: Nov 20, 2024 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
1
Any phase or sponsor naming "MBS303"
First trial start
2023
Jun 28, 2023
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "MBS303", any sponsor or status.
Conditions studied
As listed on its trial records.
- Non-Hodgkin's Lymphoma
Approved drugs for the same conditions: Lymphoma (non-Hodgkin) · Hematology and blood cancers
Largest trials
Live from ClinicalTrials.gov: studies naming "MBS303" as an intervention, largest first.
Beijing Mabworks Biotech Co., Ltd.Industry
NCT05806099 · 132 participants (planned) · Start Jun 28, 2023 · Primary completion Nov 2025
Drug: MBS303 · For: Non-Hodgkin's Lymphoma
Sites: Beijing, China
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Also in development for Non-Hodgkin's Lymphoma
- GNC-038Phase 24 trials
Sichuan Baili Pharmaceutical Co., Ltd. · Non-hodgkin's Lymphoma, Primary Central Nervous System Lymphoma, Secondary Central Nervous System Lymphoma
- single CNCT19Phase 23 trials
Juventas Cell Therapy Ltd. · Relapsed or Refractory Acute Lymphoblastic Leukemia, B-cell Acute Lymphoblastic Leukemia, Non-Hodgkin's Lymphoma
- GNC-035Phase 22 trials
Sichuan Baili Pharmaceutical Co., Ltd. · Relapsed/Refractory Chronic Lymphocytic Leukemia, Non-hodgkin's Lymphoma
- EB103Phase 21 trial
Estrella Immunopharma, Inc. · B-Cell Non-Hodgkin's Lymphoma (NHL), Lymphoma, Non-Hodgkins, Lymphomas Non-Hodgkin's B-Cell
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.